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Abstract
Introduction. Oxidative stress plays an important role in atherosclerosis, but numerous clinical trials have 
not confirmed a favourable effect of antioxidant supplementation. We aimed to determine the oxidative stress 
parameters in patients without clinical manifestation of vascular disease.
Material and methods. Forty-eight patients were divided into two groups in relation to the presence or 
absence of clinically silent signs of atherosclerosis (ankle-brachial index < 0.9, intima-media thickness ≥ 0.9 
mm, the presence of carotid atherosclerotic plaques, silent ischaemia in a treadmill stress test or focal myocar-
dial contractility found in echocardiography). Plasma concentrations of: retinol, ascorbic acid, alpha-tocopherol 
and uric acid, as well as the products of oxidative DNA damage repair: 8-oxo-7,8-dihydro-2’-deoxyguanosine 
(8-oxodG) in blood leucocytes and urine, and 8-oxo-7,8-dihydroguanine (8-oxo-Gua) in urine. 
Results. Patients with signs of subclinical atherosclerosis had lower blood concentration of alpha- tocopherol, 
and a non-significantly greater urine concentration of 8-oxoGua. Women had significantly greater blood con-
centration of ascorbic acid and alpha-tocopherol, as well as lower level of retinol and uric acid. They also had 
greater leucocyte concentration of 8-oxodG. Plasma concentration of alpha-tocopherol 30.34 μM distinguished 
patients with and without signs of subclinical atherosclerosis. 
Conclusions. Oxidative stress has clinical importance in the early stages of atherosclerosis and may be helpful 
in predicting its subclinical stage. Women had higher level of antioxidant defence, which explains their natural 
protection against early atherosclerosis development. Further studies are needed to determine the usefulness 
of tocopherol determination as a biomarker for atherosclerosis risk evaluation. 
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Introduction
Oxidative stress is a result of an imbalance between 
the production of reactive oxygen species (ROS) and 
the effectiveness of ROS scavenging in antioxidant 
defence and plays a part in the pathogenesis of several 
diseases, one of which is atherosclerosis [1, 2]. It is 
the final path though which all of known atherogenesis 
risk factors (e.g. smoking, diabetes mellitus, hyperten-
sion, dyslipidaemia) lead to endothelial dysfunction. 
Oxidative stress also affects atherosclerosis plaque 
formation through the oxidation of low-density lipo-
protein (LDL). Oxidised LDL (ox-LDL) penetrates 
cell membranes, not only via LDL receptors, but also 
through scavenger receptors and phagocytosis, which 
leads to the uncontrolled accumulation of cholester-
ol in macrophages [1–4]. This process leads to the 
transformation of macrophages into foam cells. When 
cholesterol accumulation exceeds a critical value, foam 
cell disintegration occurs. Cholesterol released into 
the vascular wall provokes an inflammatory reaction 
associated with ROS overproduction in a vicious circle 
with atherosclerosis progression, the final outcome 
of which is plaque instability, rupture and arterial 
thrombosis with unfavourable clinical implications [2]. 
Oxidative stress is also an important pathomechanism 
of ischaemia/reperfusion damage of vessel’s wall, which 
leads to oxidative DNA damage, lipid peroxidation, acti-
vation of inflammatory and cytotoxic processes, activa-
tion of matrix-metalloproteinases (MMPs), recruitment 
of endothelial progenitor cells, affection of endothelial 
and vascular smooth muscle cells apoptosis, proliferation 
and differentiation, and finally to disturbance in vessel 
wall remodelling, angiogenesis and neovascularisation. 
Chronic oxidative stress interferes also with physio-
logical redox signalling during intracellular metabolic 
processes, including ATP synthesis [5]. Therefore, 
treating oxidative stress is a target for the prevention 
of atherosclerosis development and progression. How-
ever, the results of laboratory experiments on animals 
and data obtained in observational studies that showed 
negative associations between antioxidant intake and 
all-cause and cardiovascular mortality have not been 
confirmed in several randomised controlled trials (RCTs) 
[2–7]. The majority of the trials failed to find a favourable 
cardiovascular outcome for retinol (vitamin A), ascorbic 
acid (vitamin C), or tocopherol (vitamin E) supplemen-
tation [8–14]. Only a few studies revealed a favourable 
effect for vitamin E supplementation, especially in low 
doses [3]. Similarly, conflicting results of the influence 
of antioxidant-reach food consumption on surrogate 
outcomes (endothelial function, carotid intima-media 
thickness [cIMT], C-reactive protein [CRP], interleu-
kin-17 [IL-17]) have been reported [3, 8, 9, 15, 16]. 
There are contradictory results concerning the 
effect on survival between natural antioxidant intake 
in experimental and observational studies and vitamin 
supplementation in RCTs. Therefore, we assumed that, 
apart from the potential importance of providing bal-
anced and complex natural vitamins, this discrepancy 
may also result both from interpersonal differences in 
ROS production, i.a. depends on variable proinflamma-
tory phenotype expression in inflammatory cells [5] as 
well as in the bioavailability of antioxidants and individ-
ual potential for their storage and the maintenance of 
adequate and protective blood concentrations [17, 18]. 
We hypothesised that patients with high levels of 
oxidative stress or a depletion in natural antioxidant 
defence may be the most likely to benefit from anti-
oxidant therapy or e.g. exercise training. Therefore, 
the natural or interventional intake of antioxidants 
might not be a good parameter for the evaluation 
of the importance of oxidative stress in the course 
of cardiovascular diseases. As a result, we based our 
study on plasma and urine determination of oxidative 
stress parameters, such as products of DNA damage, 
e.g. 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxo-dG) 
in leucocyte DNA, and the urinary excretion of 
the products of oxidative DNA damage repair, e.g. 
8-oxo guanine (8-oxo-Gua) and 8-oxo-dG, as well as 
on blood determination of parameters of antioxidant 
defence, such as retinol (vitamin A), ascorbic acid 
(vitamin C), tocopherol (vitamin E), uric acid, glu-
tathione, antioxidative enzymes, etc. [19–25]. The aim 
of this study, which was performed with adult patients 
without clinical manifestation of vascular diseases, was 
to compare the levels of these substances between 
individuals with and without signs of atherosclerosis. 
Material and methods
Forty-eight patients with a mean age of 56.4 ± 
4.8 years were studied. Twenty eight (58%) of them 
were males and 20 (42%) were females (Table 1). The 
inclusion criteria were as follows: lack of any acute and 
chronic disorders which could affect determinations 
of oxidoreductive balance, lack of history of acute 
coronary syndrome, myocardial infarction, stroke, 
transient ischaemic attack, intermittent claudication, 
aortic aneurysm or other vascular diseases, over the 
age of 18 and able to give informed consent for par-
ticipation in the study. The exclusion criteria were as 
follows: symptoms of any vascular diseases, diabetes 
mellitus (as an equivalent of vascular diseases), intake 
of diet supplements which could affect oxidoreductive 
balance, the inability to perform a treadmill stress test, 
and history or physical signs of inflammatory diseases 
or neoplasm. In all the patients who qualified for the 
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or n, %. The statistical significance of the differences 
between the groups was verified using the Student’s 
t-test and chi-squared test. The statistical significance 
level was set at a p-value < 0.05. Logistic regression 
using a quasi-Newton and simplex estimation method 
was applied to check the relationships between the 
presence of subclinical signs of atherosclerotic lesions 
and the variables analysed. The receiver operating 
characteristic (ROC) curve for associations between 
the presence of signs of subclinical atherosclerosis 
and the level of respective oxidoreductive balance 
parameters were determined. 
Results
Of the 48 study participants with a mean age of 56.4 
± 4.8 years, 28 (58%) were males. The established 
signs of subclinical atherosclerosis defined above were 
found in 14 (29%) subjects, 8 (57%) had cIMT greater 
than 0.9 mm, 4 (29%) had ABI < 0.9, and 2 (14%) had 
asymptomatic decrease in ST interval during treadmill 
stress test and the presence of a regional reduction in 
myocardial contractility in echocardiography. Patients 
with subclinical atherosclerosis were similar to their 
counterparts in relation to the majority of the charac-
teristics, although they were older and had a greater 
pulse pressure (the difference between systolic and 
diastolic blood pressure) (Table 1). Patients with signs 
of subclinical atherosclerosis had lower blood con-
centration of alpha- tocopherol, and non-significantly 
greater urine concentration of 8-oxo-Gua (Table 2). 
The remaining levels of the other studied parameters 
of oxidoreductive balance were similar in both groups. 
When we have compared female and male patients 
(Table 3), we have found that women had significantly 
greater blood concentrations of vitamins C and E, as 
well as lower levels of vitamin A and uric acid. Women 
also had higher level of 8-oxodG in leucocytes. 
As the intake of natural or artificial antioxidants 
might have affected the results obtained and been 
a potential confounding factor, we have compared the 
levels of the studied parameters of oxidoreductive 
balance between the patients divided in relation to 
the number of days of vegetables and fruit in their diet 
per week. However, we have not found any significant 
differences in the values of the oxidoreductive balance 
biomarkers investigated between these groups (detailed 
data are not presented). 
Next, we have performed multifactorial analysis 
using logistic regression (Table 4). We have found that 
the risk of the presence of subclinical signs of athero-
sclerosis increased significantly with the patient’s age 
(odds ratio [OR]; 1.47 ± 95% confidence interval [CI] 
study, medical histories (symptoms, past history of 
diseases, use of stimulants, intake of vegetables and 
fruit in everyday diet, and use of diet supplements 
and vitamins) were obtained, and physical exam-
ination and basic laboratory investigations (blood 
morphology, determinations of creatinine, sodium, 
potassium glucose, alanine aminotransferase, C-reac-
tive protein, total, LDL and high-density lipoprotein 
[HDL] cholesterol, and triglycerides) were performed. 
Moreover, the following were determined in all the 
subjects:  ankle-brachial index (ABI), duplex ultra-
sound of carotid arteries with an estimation of cIMT, 
electrocardiogram (ECG), treadmill stress test on 
a running track in accordance with the Bruce protocol, 
and echocardiography readings. Markers of subclinical 
vascular injury were arbitrarily established: an ABI 
cut-off value for lower limb ischaemia was established 
at < 0.9 [26], a diagnosis of atherosclerotic plaques 
in the carotid arteries was indicated by a cIMT > 0.9 
mm, signs of silent ischaemia during a treadmill stress 
test (a decrease of ST interval of more than 1 mm in at 
least two leads) or the presence of a regional reduction 
in myocardial contractility in echocardiography. On 
the basis of these criteria, the patients were divided 
into two groups: with and without at least one of the 
mentioned signs of subclinical atherosclerosis. 
Moreover, detailed examinations of oxidoreduc-
tive balance were performed as previously described 
[19–22]: 
 — in plasma: the concentration of high-sensitivity CRP 
(hs-CRP), as well as retinol (vitamin A), ascorbic 
acid (vitamin C), tocopherol (vitamin E), and uric 
acid;
 — in blood leucocytes’ DNA: 8-oxo-7,8-dihy-
dro-2’-deoxyguanosine (8-oxodG);
 — in urine: the level of 8-oxo-7,8-dihydroguanine 
(8-oxoGua) and 8-oxo-7,8-dihydro-2’-deoxy-
guanosine (8-oxodG).
Bioethics
The study protocol was approved by the local 
Bioethical Committee, and the study was conducted 
in compliance with the Declaration of Helsinki for 
medical research. All the patients signed informed 
consent for participation in the study. 
Statistics 
Statistical analysis was conducted using licensed ver-
sions of statistical software STATISTICA (a data analy-
sis software system), StatSoft, Inc. (2015), version 12. 
The normal distribution of the study variables was 
checked using the Shapiro-Wilk test. The results were 
mainly presented as the mean ± standard deviation, 
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Table 1. Comparison of clinical and biochemical data in individuals with and without subclinical signs of atherosclerosis 
Parameter
Individuals without subclinical signs of 
atherosclerosis 
n = 34 (71%)
Individuals with subclinical signs of 
atherosclerosis 
n = 14 (29%)
P
Age (years) 55.4 ± 4.3 58.8 ± 5.1 0.02
Male gender (n, %) 19 (56%) 9 (64%) 0.83
Smoking (n, %) 5 (15%) 3 (21%) 0.88
Hypertension (n, %) 6 (18%) 6 (43%) 0.14
BMI (kg/m2) 27.1 ± 3.8 28.6 ± 3.3 0.21
WHR 0.86 ± 0.08 0.88 ± 0.09 0.42
Systolic blood pressure (mm Hg) 122.2 ± 15.4 129.6 ± 15.7 0.14
Diastolic blood pressure (mm Hg) 75.6 ± 10.6 76.1 ± 10.1 0.89
Pulse pressure (mm Hg) 46.6 ± 9.7 53.6 ± 10.3 0.03
Leucocytes (G/l) 6.1 ± 1.7 6.6 ± 0.9 0.35
Erythrocytes (T/l) 4.9 ± 0.5 4.9 ± 0.3 0.99
Haemoglobin (g/dl) 14.6 ± 1.2 15.0 ± 0.7 0.24
Platelets (G/l) 244.7 ± 53.7 238.1 ± 40.6 0.68
Creatinine (mg/dl) 1.1 ± 0.2 1.1 ± 0.1 0.55
Blood glucose (mg/dl) 94.1 ± 14.2 102.8 ± 24.9 0.13
Alanine aminotransferase (U/l) 25.7 ± 8.3 32.6 ± 16.3 0.06
CRP (mg/l) 1.9 ± 4.0 1.3 ± 1.1 0.55
Total cholesterol (mg/dl) 226.9 ± 39.0 207.1 ± 31.6 0.09
HDL cholesterol (mg/dl) 58.7 ± 12.7 59.9 ± 13.4 0.77
LDL cholesterol (mg/dl) 139.6 ± 31.9 130.2 ± 26.7 0.33
Triglycerides (mg/dl) 122.4 ± 44.5 108.8 ± 33.9 0.30
Data presented as the mean ± standard deviation (SD) and number (n, %) for qualitative variables; BMI — body mass index; WHR — waist-to-hip circumference 
ratio; CRP — C-reactive protein; HDL — high-density lipoprotein; LDL — low-density lipoprotein
Table 2. Biomarkers of oxidative stress in individuals with and without subclinical signs of atherosclerosis 
Parameter
Individuals without subclinical signs 
of atherosclerosis 
n = 34 (71%)
Individuals with subclinical signs of 
atherosclerosis 
n = 14 (29%)
P
Plasma hs-CRP (mg/l) 2.56 ± 5.7 1.60 ± 1.3 0.54
Plasma CRP (mg/l) 1.98 ± 4.0 1.33 ± 1.1 0.55
Plasma ascorbic acid (µM) 38.9 ± 20.7 36.6 ± 25.5 0.74
Plasma retinol (µM) 2.8 ± 0.6 2.8 ± 0.7 0.92
Plasma alpha-tocopherol (µM) 34.2 ± 6.01 29.95 ± 5.7 0.03
Plasma uric acid (µM) 345.4 ± 61.4 346.2 ± 65.3 0.97
Creatinine in urine (mmol/l) 11.2 ± 5.66 11.38 ± 6.22 0.92
8-oxo-Gua in urine 
(nmol/mmol creatinine)
7.4 ± 3.1 12.5 ± 19.9 0.18
8-oxo-dG in urine 
(nmol/mmol creatinine)
2.4 ± 1.6 2.7 ± 1.8 0.62
8-oxo-dG in leucocytes 
(8-oxo-dG/106 dG)
6.8 ± 2.1 6.2 ± 2.0 0.40
Data presented as the mean ± standard deviation (SD) and number (n, %) for qualitative variables. The statistical significance level was set at a p-value < 0.05; 
8-oxo-Gua in urine — concentration of 8-oxoguanine in urine calculated in relation to the concentration of creatinine; 8-oxo-dG in urine — concentration of 
8-oxo-7,8-dihydro-2’-deoxyguanosine in urine calculated in relation to the concentration of creatinine; 8-oxo-dG in leucocytes — 8-oxo-7,8-dihydro-2’-deoxygua-
nosine content in leucocytes; CRP — plasma concentration of C-reactive protein; hs-CRP — plasma concentration of C-reactive protein determined using the high-
-sensitivity method
1.05–2.05; p = 0.02) and decreased with an increase 
in tocopherol blood concentration (OR 0.67; 95% CI 
0.45–1.00; p = 0.05). 
Using ROC curve analysis, we have found that plas-
ma concentration of tocopherol at the level of 30.34 
µM distinguished patients with and without signs of 
subclinical atherosclerosis (Fig. 1). 
Discussion
In this study, we have investigated the levels of 
oxidoreductive balance parameters in adults without 
clinical manifestation of vascular diseases. We have 
found that the presence of subclinical signs of athero-
sclerosis (reduced ABI, increased cIMT, the presence 
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Table 3. Biomarkers of oxidative stress in female and male patients 
Parameter Females N = 20 (42%)
Males 
N = 28 (58%) p
Plasma hs-CRP (mg/l) 3.36 ± 7.3 1.50 ± 1.57 0.19
Plasma CRP (mg/l) 2.59 ± 5.1 1.48 ± 1.09 0.17
Plasma ascorbic acid (µM) 49.5 ± 22.6 30.2 ± 17.8 < 0.01
Plasma retinol (µM) 2.6 ± 0.5 3.0 ± 0.7 0.04
Plasma alpha-tocopherol (µM) 35.4 ± 5.7 31.2 ± 6.0 0.02
Plasma uric acid (µM) 317.4 ± 42.4 365.9 ± 66.2 < 0.01
Creatinine in urine (mmol/l) 7.4 ± 4.1 14.1 ± 5.2 < 0.01
8-oxo-Gua in urine 
(nmol/mmol creatinine) 8.0 ± 3.6 9.2 ± 13.1 0.73
8-oxo-dG in urine 
(nmol/mmol creatinine) 2.9 ± 2.0 2.3 ± 1.3 0.24
8-oxo-dG in leucocytes 
(8-oxo-dG/106 dG) 7.5 ± 2.6 6.1 ± 1.4 0.03
Data presented as the mean ± standard deviation (SD) and number (n, %) for qualitative variables. The statistical significance level was set at a p-value < 0.05; 8-oxo-
-Gua in urine — concentration of 8-oxoguanine in urine calculated in relation to the concentration of creatinine; 8-oxo-dG in urine — concentration of 8-oxo-7,8-
-dihydro-2’-deoxyguanosine in urine calculated in relation to the concentration of creatinine; 8-oxo-dG in leucocytes — 8-oxo-7,8-dihydro-2’-deoxyguanosine content 
in leucocytes; CRP — plasma concentration of C-reactive protein; hs-CRP — plasma concentration of C-reactive protein determined using the high-sensitivity method 
Table 4. Factors determining the risk of the presence of clinically silent atherosclerotic lesions; Chi2 (5) = 24.50; p < 0.001
Parameter Constant Age Current  smoker Tocopherol 8-oxo-Gua_U 8-oxo-dG_L
Estimation –9.62 0.39 0.26 –0.40 0.09 –0.40
Standard error 8.26 0.16 2.35 0.19 0.07 0.43
p 0.25 0.02 0.91 0.05 0.19 0.36
-95% CI –26.45 0.05 –4.52 –0.79 –0.05 –1.27
+95% CI 7.21 0.72 5.04 –0.00 0.24 0.47
Wald test Chi square 1.36 5.55 0.01 4.21 1.83 0.87
P 0.24 0.02 0.91 0.04 0.18 0.35
OR for one unit 0.00 1.47 1.30 0.67 1.10 0.67
-95% CI 0.00 1.05 0.01 0.45 0.95 0.28
+95% CI 1350.50 2.05 154.12 1.00 1.27 1.60
8-oxo-Gua_U — 8-oxoguanine in urine; 8-oxo-dG_L — 8-oxo-7,8-dihydro-2’-deoxyguanosine in leucocytes; CI — confidence interval; OR — odds ratio
Figure 1. The ROC curve for associations between blood 
vitamin E concentration and the presence of clinically silent 
atherosclerotic lesions
of atherosclerotic plaques in the common carotid 
artery, signs of silent myocardial ischaemia during a 
treadmill stress test or in transthoracic echocardiog-
raphy) were independently and positively related to 
the patient’s age and negatively with blood tocopherol 
concentration (Table 2, Table 4). The presence of 
subclinical signs of atherosclerosis was also related 
to an increased stiffness of the arterial wall expressed 
by greater pulse pressure (the difference between 
systolic and diastolic blood pressure) (Table 1). This 
observation suggests that stronger antioxidant defence 
in blood may protect patients against the development 
of atherosclerotic plaque and arterial stiffness, which 
are recognised as independent risk factors of cardio-
vascular death. Moreover, we have found that female 
patients had greater blood concentrations of vitamins 
C and E, and lower blood vitamin A concentration 
(Table 3), which might be directly linked with the 
later development of atherosclerosis in women [27]. 
Blood concentration of vitamin E lower than 30.34 
µM (Figure 1) was the only oxidoreductive parameter 
which was predictive of the presence of clinically silent 
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atherosclerotic lesions or arterial stiffness (greater 
pulse pressure). 
Our results concerning the potential anti-athero-
genic properties of vitamin E are consistent with the 
results of a recent meta-analysis of observational studies 
made by Li et al. [28], in which blood concentration of 
total tocopherol was significantly lower in coronary 
artery disease (CAD) patients than that in controls. 
In this study, lower blood level of total tocopherols 
was also associated with early CAD onset. Similarly, in 
the Asymptomatic Carotid Atherosclerotic Disease in 
Manfredonia Study, patients with cIMT ≥ 0.8 mm had 
significantly lower blood concentration of vitamins A 
and E and beta-carotene than participants who did not 
show evidence of carotid atherosclerosis [29]. Our 
results also corroborate data reported in numerous ob-
servational and real-world studies, such as the Harvard 
Nurses’ Health Study (NHS) and the Health Professional 
Study (HPS), which showed a cardioprotective effect of 
vitamin E supplementation [30]. Previously, Stephens 
et al. [31] in their Cambridge Heart Antioxidant Study 
(CHAOS), and, recently, Loffredo et al. [32], also found 
a reduced risk of myocardial infarction among patients 
on vitamin E supplementation. Cardioprotective prop-
erties of vitamin E supplementation were also revealed 
in a recent meta-analysis by Schwingshackl et al. [12]. 
However, some observational investigations found that 
the consumption of vitamin C, vitamin E and beta-car-
otene was not related to cardiovascular disease (CVD) 
mortality in women or to cancer mortality in either 
gender (the HAPIEE study) [14]. Large randomised pla-
cebo-controlled trial such as the HOPE Study [33, 34], 
and older [35] and more recent [9, 10, 36–38] meta- 
analyses have shown that vitamin E supplementation 
had no beneficial or adverse effect on cardiovascular 
outcomes, and may even have increased all-cause mor-
tality [39]. Moreover, the above-cited recent meta-anal-
ysis by Schwingshackl et al. [12] showed that the intake 
of beta-carotene may be associated with increased risk 
of all-cause mortality. This observation may corrobo-
rate our observation in female patients (Table 3), who 
had a lower level of circulating vitamin A and were 
recognised as having reduced cardiovascular risk [27]. 
However, Koh et al. [40] and Gey et al. [41] showed 
a decreased risk of myocardial infarction in Chinese 
patients with high plasma levels of b-cryptoxanthin and 
lutein, and increased risk of coronary events in patients 
with low blood retinol concentration, respectively. Var-
ious attempts were made by the researchers to explain 
these contradictory outcomes as the effect of known 
and unknown drug-drug interactions or unexpected 
adverse drug reactions [30], because antioxidant vita-
mins in those RCTs were added to each patient’s usual 
dietary regimen. One important factor in explaining 
the contrary findings of the effect of vitamin E on the 
course of vascular and neoplasmatic diseases might 
also be the different vitamin E doses given in respective 
investigations, which ranged from 300 to 1800 IU per 
day [42], and the absence of gamma-tocopherol in tra-
ditional preparations [43]. This member of tocopherol 
family exerts stronger cardioprotective, antioxidant and 
anti-inflammatory effects than alpha-tocopherol [43]. 
In our work, we have not only studied the concen-
tration of antioxidant vitamins in blood, but also the 
level of oxidatively damaged DNA in urine and leuco-
cytes. We have found a non-significantly greater urine 
concentration of 8-oxoGua in patients with clinically 
silent signs of atherosclerosis (Table 2). Różalski et 
al. [19] found that patients, who qualified for carotid 
endarterectomy and had echolucent carotid plaques 
(gray-scale median score < 25), had also the highest 
antioxidant level and lowest excretion of DNA repair 
markers than remained patients and control. In a study 
by Sigala et al. [25], a higher level of oxidative stress 
expressed by the presence of ox-LDL in blood was 
associated with the presence of symptoms of carotid 
atherosclerotic plaque instability. No effect of antiox-
idants on cIMT was previously reported either [16]. 
These data confirm the clinical importance of distur-
bances in oxidoreductive balance in the pathogenesis 
of atherosclerosis, and suggest that serum antioxidant 
level, especially vitamin E, may act as a biomarker for 
the risk of atherosclerosis [19, 44]. 
Although we have found some statistically signifi-
cant differences between the studied parameters, our 
results may have shortcomings which could decrease 
the strength of our deductions. Firstly, the studied 
group was small and potential confounding factors 
as age and gender were not balanced, but this au-
thenticates the significance of the differences found. 
Secondly, a diagnosis of clinically silent atherosclerosis 
was based on non-invasive examinations and was grad-
ed only on two levels (present or absent). Thirdly, the 
consumption of fruit and vegetables was determined by 
a qualitative scale in a questionnaire only, and patients’ 
diet before blood examination was not standardised. 
However, it was previously revealed that the level 
of some parameters of oxidative stress does not de-
pend on diet [22]. Fourthly, we have determined only 
alpha-tocopherol from the tocopherol family, but cur-
rently gamma-tocopherol seems to be more important 
in cardioprotection [43]. 
In conclusion, our pilot study on a small number 
group of patients pointed out the potential importance 
of alpha-tocopherol blood concentration in the early 
stages of atherosclerosis and showed that its determi-
nation may be helpful in predicting its subclinical stage. 
Women had a higher level of alpha-tocopherol and 
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ascorbic acid, which may explain their natural protec-
tion against early atherosclerosis development, in spite 
of lower level of retinol and uric acid. Differences in the 
weekly intake of fruit or vegetables had no effect on 
the plasma level of the parameters of oxidoreductive 
balance studied, but, due to study limitations, this as-
sociation needs to be evaluated in a larger sample size. 
Further studies in the large sample size are also needed 
to determine the usefulness of vitamin E determination 
as a biomarker of atherosclerosis risk. 
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